Search

for
Search:

Glossary Imatinib

targets specific enzymes to treat certain cancers like CML

Imatinib, also known as Gleevec, is a targeted cancer therapy drug used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It works by inhibiting specific tyrosine kinases, which are enzymes that promote the growth of cancer cells, thereby slowing or stopping the progression of the disease.

Related Terms

Sort by

Community Join

30 / 1000+ results

community Ways to prevent hair from becoming grey or delaying the greying of hairs? (Have You Heard of Catalase!?)

23 upvotes 1 year ago

Catalase is discussed as a potential treatment for delaying or reversing grey hair, but no reliable medicine currently exists. Other mentioned treatments include Imatinib, senolytics like Quercetin and Fisetin, He Shou Wu, Argan oil, and reishi mushroom extract, though their effectiveness varies.

community We should actually be hopeful for these recent new developments

112 upvotes 1 year ago

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

community How promising is kintor pyrilutamide?

in Treatment 13 upvotes 4 years ago

The conversation discusses the potential of kintor pyrilutamide as a promising treatment for hair loss, with ongoing trials in various phases. There is skepticism due to delays in trial results, but the company is actively pursuing further trials.

community when is kintor going to start phase 3 for gt20029?

6 upvotes 2 years ago

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

community IGE Hair Loss and Miniaturization

in Chat 3 upvotes 1 year ago

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

community Kintor long term safety phase 3

in Research/Science 66 upvotes 1 year ago

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

community GT20029 & KX826 Major Updates from Kintor.

101 upvotes 1 year ago

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

community Kintor money grab, unacceptable

in Product 76 upvotes 1 year ago

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

community Potentially Positive Pyrilutamide News Coming

6 upvotes 6 months ago

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

community Q1 2024 is done. And kintor is completely silent about GT20029.

31 upvotes 2 years ago

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

community Kintor starts a new Phase 3 for Pyri... (1+ year)

16 upvotes 3 years ago

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

community Kintor announcement about pyrilutamide phase 3 results in CHINA

15 upvotes 2 years ago

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

90 upvotes 3 years ago

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

community Kintors 1% Pyrilutamide comes in October/November

in Treatment 21 upvotes 2 years ago

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

community When will GT20029 phase 3 trial begin?

11 upvotes 1 year ago

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

17 upvotes 4 years ago

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

community Kintor 0.9% , save your money friends

in Minoxidil 9 upvotes 5 months ago

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

community Kintor stealing pictures from a hair transplant clinic to promote their failed product (KX826, Pyrilutamide)

in Product 314 upvotes 2 years ago

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

community Anyone immediately lose hope for gt20029 when they realised it’s developed by kintor

7 upvotes 8 months ago

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

community When do you guys think we’ll be able to get our hands on kintor pyrilutamide?

16 upvotes 4 years ago

Pyrilutamide, a hair loss treatment, is undergoing clinical trials in China and may be available in a few years. Users discuss the possibility of obtaining it early through group buys and synthesis by labs.

community Anyone heard of or have experience using baricitinib?

1 upvotes 3 years ago

The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.

community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.

156 upvotes 1 year ago

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

community Article of all potential future cures

25 upvotes 1 year ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

community Kintors interim report from 9-2-24 for everyone whos interested

32 upvotes 2 years ago

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA

13 upvotes 3 years ago

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

community Show of hands (US people), who's ordering pyrilutamide?

in Treatment 7 upvotes 2 years ago

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

community How much faith do you have in Kintor?

18 upvotes 4 years ago

KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.

community Kintor going after Pelage? KT-215

9 upvotes 2 weeks ago

Kintor is potentially pursuing a new hair loss treatment, KT-215, while users express skepticism about the speed and reliability of new product releases. There is a general sentiment that Chinese companies might be more promising in delivering timely solutions.

community Pyrilutamide with Alfatradiol and minoxidil (23M)

in Treatment 2 upvotes 9 months ago

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.

community GT20029 - Promising phase II results

16 upvotes 2 years ago

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.